Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Centerpulse/Sulzer Cuts Settlement Opt-Outs To 87, Sidesteps Bankruptcy

This article was originally published in The Gray Sheet

Executive Summary

Centerpulse plans to "aggressively defend" in court any outstanding claims related to its Inter-Op hip implant and Natural Knee II recalls that were not part of a class settlement, but the firm has not ruled out the possibility of settling those claims out of court

You may also be interested in...



Physician-Initiated Alert Sparks Zimmer Investigation Of Durom Hip Failures

Zimmer is investigating failures of its Durom hip implants after a prominent joint reconstruction surgeon sent a letter reporting a series of problems with the device to the American Association of Hip and Knee Surgeons

Physician-Initiated Alert Sparks Zimmer Investigation Of Durom Hip Failures

Zimmer is investigating failures of its Durom hip implants after a prominent joint reconstruction surgeon sent a letter reporting a series of problems with the device to the American Association of Hip and Knee Surgeons

Zimmer Pursuing Low-Cost DTC Strategy For MIS 2 Incision Hip Surgery

Obtaining local media coverage for Zimmer's MIS 2 incision hip replacement procedure is proving to be a cost-effective DTC strategy, according to CEO Ray Elliott

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT016649

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel